Literature DB >> 9239408

Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b.

S Chabot1, G Williams, V W Yong.   

Abstract

TNF-alpha is a proinflammatory cytokine involved in many inflammatory conditions such as Crohn's disease, rheumatoid arthritis, cachexia, AIDS, and multiple sclerosis (MS). TNF-alpha is produced mainly by cells of the macrophage lineage, which includes microglia in the central nervous system. Here, we describe a mechanism through which TNF-alpha is generated by microglia. We show that activated human T lymphocytes induce the microglial production of TNF-alpha, and that is attenuated by a functional blocking antibody to CD49d, the alpha chain of the VLA-4 integrin on T cells. We also report that interferonbeta-1b (IFNbeta-1b), a drug that alleviates symptoms in MS, downregulates the expression of CD49d and reduces TNF-alpha production, mechanisms which can help account for its efficacy in MS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9239408      PMCID: PMC508228          DOI: 10.1172/JCI119571

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial.

Authors:  O Fernández; A Antiquëdad; T Arbizu; A Capdevíla; P de Castro; J C Correa de Sa; J A García-Merino; G Izquierdo; A Magalhaes; X Montalbán
Journal:  Mult Scler       Date:  1995       Impact factor: 6.312

2.  Interferon in experimental autoimmune encephalomyelitis (EAE): effects of exogeneous interferon on the antigen-enhanced adoptive transfer of EAE.

Authors:  S L Abreu
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

3.  In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta.

Authors:  R A Rudick; C S Carpenter; D L Cookfair; V K Tuohy; R M Ransohoff
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

4.  Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro.

Authors:  K W Selmaj; C S Raine
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

5.  Morphological changes in oligodendrocytes in the intact mouse optic nerve following intravitreal injection of tumour necrosis factor.

Authors:  A M Butt; H G Jenkins
Journal:  J Neuroimmunol       Date:  1994-04       Impact factor: 3.478

Review 6.  The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion.

Authors:  C S Raine
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

7.  Reduction of immunoglobulin G secretion in vitro following long term lymphoblastoid interferon (Wellferon) treatment in multiple sclerosis patients.

Authors:  M R O'Gorman; J Oger; L F Kastrukoff
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

8.  Multiple sclerosis: distribution of T cell subsets within active chronic lesions.

Authors:  U Traugott; E L Reinherz; C S Raine
Journal:  Science       Date:  1983-01-21       Impact factor: 47.728

9.  Experimental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction. Severe paralytic disease correlates with the presence of interleukin 2 receptor-positive cells infiltrating the central nervous system.

Authors:  J Sedgwick; S Brostoff; D Mason
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

10.  Tumor necrosis factor identified in multiple sclerosis brain.

Authors:  F M Hofman; D R Hinton; K Johnson; J E Merrill
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

View more
  32 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

Authors:  R Hohlfeld
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

3.  3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists.

Authors:  Juswinder Singh; Herman van Vlijmen; Wen-Chemg Lee; Yusheng Liao; Ko-Chung Lin; Humayun Ateeq; Julio Cuervo; Craig Zimmerman; Charles Hammond; Michael Karpusas; Rex Palmer; Tapan Chattopadhyay; Steven P Adams
Journal:  J Comput Aided Mol Des       Date:  2002-03       Impact factor: 3.686

Review 4.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 5.  First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Authors:  Jessica Johnston; Tsz-Yin So
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

6.  Stimulation of adult oligodendrogenesis by myelin-specific T cells.

Authors:  Helle Hvilsted Nielsen; Henrik Toft-Hansen; Kate Lykke Lambertsen; Trevor Owens; Bente Finsen
Journal:  Am J Pathol       Date:  2011-08-26       Impact factor: 4.307

7.  Induction of Adaptive Immunity Leads to Nigrostriatal Disease Progression in MPTP Mouse Model of Parkinson's Disease.

Authors:  Goutam Chandra; Avik Roy; Suresh B Rangasamy; Kalipada Pahan
Journal:  J Immunol       Date:  2017-04-26       Impact factor: 5.422

Review 8.  A Critical Review of Microelectrode Arrays and Strategies for Improving Neural Interfaces.

Authors:  Morgan Ferguson; Dhavan Sharma; David Ross; Feng Zhao
Journal:  Adv Healthc Mater       Date:  2019-08-28       Impact factor: 9.933

9.  Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis.

Authors:  Subhajit Dasgupta; Malabendu Jana; Xiaojuan Liu; Kalipada Pahan
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

10.  Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected] integrin.

Authors:  Avik Roy; Xiaojuan Liu; Kalipada Pahan
Journal:  J Biol Chem       Date:  2007-09-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.